bevacizumab + S-1

Bevacizumab + S-1 is a combination chemotherapy regimen consisting of bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), and S-1, an oral fluoropyrimidine derivative that acts as a prodrug of 5-fluorouracil (5-FU). Bevacizumab inhibits angiogenesis by binding to VEGF-A, thereby preventing the growth of new blood vessels essential for tumor survival and proliferation. S-1 combines tegafur (a 5-FU prodrug) with two modulators—gimeracil and oteracil—to enhance efficacy and reduce gastrointestinal toxicity. This combination has been studied primarily in metastatic colorectal cancer (mCRC), non-squamous non-small cell lung cancer (NSCLC), and oral squamous cell carcinoma (OSCC). Clinical studies suggest it can be administered safely on an outpatient basis, with manageable toxicity profiles. The regimen is particularly considered for elderly patients or those who may not tolerate more intensive chemotherapy[1][2][4][5].

Brand names

AvastinMvasiAlymsysJobevneVegzelmaZirabev

Other names

bevacizumab + S-1bevacizumab combined with S-1